Yahoo
NasdaqGS - BOATS Real Time Price USD

ICON Public Limited Company (ICLR)

214.16 +31.18 (+17.04%)
At close: October 28 at 4:00:00 PM EDT
215.00 +0.84 (+0.39%)
Overnight: 3:18:05 AM EDT
Trade ICON on Coinbase
ICLR Q3 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for ICLR
Chart does not reflect overnight price.
  • Previous Close 182.98
  • Open 199.19
  • Bid 212.84 x 100
  • Ask 212.96 x 100
  • Day's Range 195.99 - 214.94
  • 52 Week Range 66.57 - 214.94
  • Volume 3,944,352
  • Avg. Volume 901,126
  • Market Cap (intraday) 16.523B
  • Beta (5Y Monthly) 1.24
  • PE Ratio (TTM) 85.66
  • EPS (TTM) 2.50
  • Earnings Date Oct 27, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 188.24
  • Morningstar Rating Rating available with Stock Picks access

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

www.iconplc.com

40,200

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ICLR
17.53%
S&P 500 (^GSPC)
13.13%

1-Year Return

ICLR
20.50%
S&P 500 (^GSPC)
12.38%

3-Year Return

ICLR
8.99%
S&P 500 (^GSPC)
88.08%

5-Year Return

ICLR
25.23%
S&P 500 (^GSPC)
68.48%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 2.02B
Earnings 122.13M
Profit Margin 6.03%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
500M
1B
2B
2B
4.0%
5.0%
6.0%
7.0%

Analyst Insights

View More

Analyst Price Targets

155.00 Low
188.24 Average
214.16 Current
215.00

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/18/2026
Analyst Citigroup
Rating Action Maintains
Rating Neutral
Price Action Lowers
Price Target 180 -> 175

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.33%

  • Return on Assets (ttm)

    0.97%

  • Return on Equity (ttm)

    0.29%

  • Revenue (ttm)

    8.29B

  • Net Income Avi to Common (ttm)

    27.04M

  • Diluted EPS (ttm)

    2.50

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    928.39M

  • Total Debt/Equity (mrq)

    37.60%

  • Levered Free Cash Flow (ttm)

    622.65M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: